M&A · Healthcare · Pharmaceutical Preparations
SERB Pharmaceuticals to acquire Y-mAbs Therapeutics, Inc.
Announced Aug 5, 2025 · Closed Sep 16, 2025
Deal value$412MEV $352M
Premium105.0%To unaffected price
EV / Adj. EBITDA—4.0x EV / Revenue
ConsiderationAll cash$8.60 per share
Transaction
- Acquirer
- SERB Pharmaceuticals
- Target
- Y-mAbs Therapeutics, Inc. (YMAB)
- Buyer type
- Strategic
- Offer price per share
- $8.60
- Enterprise value
- $352M
- Status
- Closed Sep 16, 2025
Deal protections
- Break fee (target pays)
- $14.3M · 3.5%
- Reverse fee (buyer pays)
- —
- Go-shop
- No-shop
- Financing
- No financing condition
Advisors
- To the acquirer
- Rothschild & Co
- To the target
- Centerview
- Centerview fee
- $9.1M
Sector context · Healthcare
- Comparable deals
- 97 in the prior 24 months
- Premium
- 105.0% vs. 67.0% sector median
- EV / Adj. EBITDA
- Sector median 14.5x
- Break fee
- 3.5% vs. 3.4% sector median
Timeline
- AnnouncedAug 5, 2025
- Tender offerAug 18, 2025
- ClosedSep 16, 2025
Valuation · fairness opinions
Trading comparables$3.30$6.50
Precedent transactions$4.20$8.25
Discounted cash flow$6.85$8.85
Analyst price targets$3.00$26.00
Premiums paid$5.85$10.05
Offer $8.60
Implied value per Y-mAbs Therapeutics, Inc. share by analysis, from Centerview · DCF discount rate 14.5%–16.5%.